Seeking Alpha

Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceutical days the FDA has approved a...

Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceutical days the FDA has approved a broader indication for Zytiga. The drug, in combination with prednisone, may now be used earlier in the treatment continuum, before the use of chemotherapy. Zytiga also received a positive opinion for an expanded indication from the EMA and is under review by other health authorities worldwide.
Comments (1)
  • Old Trader
    , contributor
    Comments (5724) | Send Message
     
    It seems that slowly, but surely, the news flow re: JNJ is turning positive.
    10 Dec 2012, 04:39 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|